Assembly Biosciences, Inc.
NASDAQ:ASMBBiotechnology
+$0.16 today
- Market cap
- $458.48M
- Beta
- 1.08
- P/E (TTM)
- -64.4
- EPS (TTM)
- -$0.38
Volume 0.49M
Average 0.17M
ASMB Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Assembly Biosciences, Inc.NASDAQ: ASMB
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow dips below year-ago levels
Q1 FY2026 financing cash flow of $149K fell 92.2% year over year, behind the +451.1% change in trailing-twelve-month financing cash flow. Sequentially, it fell 67.3% from the prior quarter. Over 3 fiscal years it compounded at +557.7% a year.
Context
- Financing cash flow amounted to 241.6% of revenue in FY2025, up 138.3 pp from a year earlier.
- Financing cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -92.2% toward the trailing-twelve-month pace of +451.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 174.67M USD
- Year-over-year change
- +493.1%
- 4-year CAGR
- +34.7%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 174.67M | +493.1% |
| FY2024 | 2024-12-31 | 29.45M | +113.1% |
| FY2023 | 2023-12-31 | 13.82M | +2150.5% |
| FY2022 | 2022-12-31 | 614K | -98.8% |
| FY2021 | 2021-12-31 | 53.06M | — |
Financing Cash Flow vs competitors
How ASMB compares with its peers on the latest reported figures
- ASMB's LTM Mar 2026 financing cash flow of $172.89M is the largest of the 6 companies compared; the peer median is $14.88M.
- Its year-over-year change of +451.1% is the 3rd highest of 6, against a peer median of +263.6%.
- Financing cash flow amounts to 243.2% of revenue for ASMB, versus a peer median of 60.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $172.89M | +451.1% | +557.7% | 243.2% | |
| LTM Mar 2026 | $165.71M | +3328.0% | -52.2% | 253.0% | |
| LTM Mar 2026 | $42.1M | +263.6% | — | 60.8% | |
| LTM Mar 2026 | $25.14M | +10830.9% | — | — | |
| LTM Mar 2026 | $14.88M | +96.2% | — | — | |
| LTM Mar 2026 | $14.56M | -52.0% | -43.6% | 7.6% | |
| Peer median (excluding ASMB) | $14.88M | +263.6% | -47.9% | 60.8% | |
Competitors are the stored peer set for ASMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (129.86M) | (93.09M) | (61.23M) | (40.18M) | (6.12M) |
| Depreciation & Amortization | 466K | 498K | 450K | 129K | 129K |
| Deferred Income Tax | (2.53M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.24M | 6.59M | 5.12M | 3.12M | 4.68M |
| Change in Working Capital | (11.4M) | (2.12M) | 76.34M | (11.95M) | (38.28M) |
| Accounts Receivables | 894K | (608K) | 901K | 43K | (974K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.94M) | (166K) | (2.03M) | 124K | 586K |
| Other Working Capital | (10.36M) | (1.35M) | 77.47M | (12.12M) | (37.89M) |
| Other Non-Cash Items | 44.69M | 3.66M | 2.06M | (2.24M) | (1.5M) |
| Operating Cash Flow | (93.4M) | (84.46M) | 22.74M | (51.12M) | (41.09M) |
| Capital Expenditures | (3.1M) | (102K) | (255K) | (28K) | (66K) |
| Acquisitions (Net) | 1.5M | 1.5M | 0 | 0 | 0 |
| Purchases of Investments | (160.45M) | (27.58M) | (133.92M) | (90.5M) | (232.18M) |
| Sales of Investments | 187.7M | 116.83M | 65.02M | 130.7M | 116.43M |
| Other Investing Activities | 857K | 0 | 24K | 0 | 2.35M |
| Investing Cash Flow | 26.52M | 90.64M | (69.14M) | 40.17M | (113.47M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 52.81M | 325K | 13.69M | 29.29M | 174.67M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 258K | 289K | 129K | 155K | 0 |
| Financing Cash Flow | 53.06M | 614K | 13.82M | 29.45M | 174.67M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (13.82M) | 6.79M | (32.58M) | 18.5M | 20.11M |
| Free Cash Flow | (96.49M) | (84.57M) | 22.49M | (51.15M) | (41.16M) |
Assembly Biosciences, Inc.
NASDAQ:ASMB
Intrinsic Alpha fair value
Locked
Current Price
$22.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.